KSF is Growing! New Research Team: Drs. Bloom and Tang

Kabuki Syndrome Foundation Appoints Dr. Bruce Bloom and Dr. Clara Tang to
Lead Treatment-Focused Research Advancements

NEW YORK, April 10, 2023—The Kabuki Syndrome Foundation (KSF) is delighted to announce the addition of Dr. Bruce Bloom and Dr. Clara Tang as Chief Scientific Officer and Director of Research, respectively. With over 20 years of combined experience in rare drug research, their expertise will significantly contribute to accelerating patient-centered Kabuki syndrome research. The integration of this dynamic team represents a crucial milestone for KSF in the creation, identification, and funding of promising projects and in preparing the Kabuki syndrome community for clinical trial success.

At the Kabuki Syndrome Foundation, Dr. Bloom will help drive the research and clinical development plans, and support gathering and coordinating with the patient advocacy, research, and clinical communities. He also serves as Chief Science Officer for Goldman Philanthropic Partnerships to support the global research funding decision-making, and is the Chief Collaboration Officer of Healx, a Cambridge, UK biotech using AI to create novel therapies for rare disease patients. Dr. Bloom founded and led the global charity Cures Within Reach that has brought over a dozen redeveloped drug therapies to patients through proof-of-concept clinical trials.

“The Kabuki syndrome community is vibrant, engaged, and poised for progress.  I am eager to work with the KSF team, the researchers, clinicians, and the community to find ways to increase knowledge and enhance lives.” said Dr. Bloom.

As the Director of Research, Dr. Tang is responsible for leading the development and execution of the Kabuki syndrome research strategy. Dr. Tang has a PhD in neuroscience from the University of Cambridge and was most recently an Alliance Strategy Manager at Healx for the past three years, where she led the development and alliance management of all collaborations with academic and patient group partners.

“KSF has an incredibly inspiring mission, community, and a fantastic team. I am very excited to combine my academic background in neuroscience with my industry knowledge in rare disease drug development to help find treatments for patients with Kabuki syndrome,” said Dr. Tang.

Janet Lee, Executive Director of KSF, says, “The addition of Drs. Bloom and Tang is an incredible win for the foundation and the Kabuki syndrome community. Our newly appointed research team not only shares our vision of accelerating treatments for individuals with Kabuki syndrome, but they bring a heightened level of experience and knowledge of rare disease drug development that brings us one step closer to realizing that vision.”

About The Kabuki Syndrome Foundation:

The Kabuki Syndrome Foundation was established in 2017 and is a US based nonprofit organization dedicated to accelerating research efforts that show promise to treat or cure Kabuki syndrome. For more information on Kabuki syndrome and how you can help drive research, visit:


Janet Lee, Executive Director
Kabuki Syndrome Foundation